Perspective Therapeutics, Inc. (CATX): EPS (Diluted)
-$1.40
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$1.40 | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$1.23 | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$1.74 | n/a | 2025-03-28, From 2023-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | -$1.40 | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$2.40 | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.06 | +165.0% |
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $3.98 | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$3.03 | n/m |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | -$2.17 | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$0.55 | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$14.57 | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$1.18 | n/m |
Compare CATX, ARCT, NATR, DMRA side by side · Screen every company in Pharmaceutical Preparations ↗